Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
VEGF Receptor Ribozyme Entered Into Product Development
November 24th, 1997
Ribozyme Pharmaceuticals, Inc. (RPI), New York, New York, announced commencement of product development activities for a ribozyme-based therapeutic directed at the vascular endothelial growth factor (VEGF) receptor. VEGF is secreted by numerous human tumors including cancers of the lung, breast, and colon. The chemically synthesized anti-VEGF receptor ribozyme (RPI.4610) has shown activity in multiple animal models of angiogenesis in the eye and in cancers. For example, in mice bearing Lewis lung carcinomas, RPI.4610 inhibited development of tumor blood vessels resulting in significant inhibition of both tumor growth and metastasis. As a result,...
Source: Cancer Weekly (1997-11-24)
|
